Form D · Other Health Care
MorphImmune Inc.
West Lafayette, IN · CIK 0001911732
Offering snapshot reported May 17, 2023 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 5, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2023 | Initial | $15,000,000 | No comparison | 11 | SEC filing |
| Feb 17, 2022 | Initial | $17,135,765 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-481899
Source: Form D, filed May 17, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Isaac Barchas | Director |
| Philip Low, Ph.D. | Director |
| Ronald Martell | Director |
| Franklyn Prendergast, M.D., Ph.D. | Director |
| Clay B. Siegall, Ph.D. | Director, Executive |
| Sunil Singhal, M.D. | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
1281 Win Hentschel Boulevard Suite 1300
West Lafayette, IN, 47906
West Lafayette, IN, 47906